Metabolic and therapeutic effects of insulin-like growth factor I

E. R. Froesch, P. D. Zenobi, M. Hussain

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)66-71
Number of pages6
JournalHormone Research in Paediatrics
Issue number1-2
StatePublished - Jan 1 1994
Externally publishedYes


  • Growth hormone inhibition
  • Insulin inhibition
  • Insulin sensitivity
  • Lipid metabolism
  • rhIGF-I therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Metabolic and therapeutic effects of insulin-like growth factor I'. Together they form a unique fingerprint.

Cite this